Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
The Netherlands Journal of Medicine
|
February 3, 2005
Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I: established and potential determinants of virological outcome
S H Lowe, J M Prins, J M A Lange
HIV Medicine
|
May 16, 2002
The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response
V Miller, T Stark, A E Loeliger, et al.
HIV Medicine
|
August 15, 2006
Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine
F van Leth, D B Hall, J M A Lange, et al.
Statistics in Medicine
|
September 5, 2002
A Bayesian approach to parameter estimation in HIV dynamical models
H Putter, S H Heisterkamp, J M A Lange, et al.
Advances in Preventive Medicine
|
April 23, 2013
North-South Corridor Demonstration Project: Ethical and Logistical Challenges in the Design of a Demonstration Study of Early Antiretroviral Treatment for Long Distance Truck Drivers along a Transport Corridor through South Africa, Zimbabwe, and Zambia
G B Gomez, W D F Venter, J M A Lange, et al.
HIV Medicine
|
January 21, 2004
Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors
P Reiss, M Casula, A de Ronde, et al.
AIDS (London, England)
|
March 15, 2005
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART
F van Leth, S Andrews, B Grinsztejn, et al.
HIV Medicine
|
February 3, 2012
Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study
S M Hermans, F van Leth, Y C Manabe, et al.
AIDS Research and Human Retroviruses
|
January 3, 2006
Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients
K Pogány, H L Zaaijer, J M Prins, et al.
HIV Medicine
|
November 5, 2005
Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009
M A Boyd, U Siangphoe, K Ruxrungtham, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
The Netherlands Journal of Medicine
|
February 3, 2005
Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I: established and potential determinants of virological outcome
S H Lowe, J M Prins, J M A Lange
HIV Medicine
|
May 16, 2002
The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response
V Miller, T Stark, A E Loeliger, et al.
HIV Medicine
|
August 15, 2006
Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine
F van Leth, D B Hall, J M A Lange, et al.
Statistics in Medicine
|
September 5, 2002
A Bayesian approach to parameter estimation in HIV dynamical models
H Putter, S H Heisterkamp, J M A Lange, et al.
Advances in Preventive Medicine
|
April 23, 2013
North-South Corridor Demonstration Project: Ethical and Logistical Challenges in the Design of a Demonstration Study of Early Antiretroviral Treatment for Long Distance Truck Drivers along a Transport Corridor through South Africa, Zimbabwe, and Zambia
G B Gomez, W D F Venter, J M A Lange, et al.
HIV Medicine
|
January 21, 2004
Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors
P Reiss, M Casula, A de Ronde, et al.
AIDS (London, England)
|
March 15, 2005
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART
F van Leth, S Andrews, B Grinsztejn, et al.
HIV Medicine
|
February 3, 2012
Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study
S M Hermans, F van Leth, Y C Manabe, et al.
AIDS Research and Human Retroviruses
|
January 3, 2006
Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients
K Pogány, H L Zaaijer, J M Prins, et al.
HIV Medicine
|
November 5, 2005
Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009
M A Boyd, U Siangphoe, K Ruxrungtham, et al.
Page
of 2